相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hypoxia in Breast Cancer-Scientific Translation to Therapeutic and Diagnostic Clinical Applications
Ying Zhang et al.
FRONTIERS IN ONCOLOGY (2021)
The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
Yue Li et al.
FRONTIERS IN PHARMACOLOGY (2021)
Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications
Rachel Shi et al.
CELLS (2021)
Preparation of polyethylene glycol-polyacrylic acid block copolymer micelles with pH/hypoxic dual-responsive for tumor chemoradiotherapy
Jiajia Weng et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2020)
Azo-inserted responsive hybrid liposomes for hypoxia-specific drug delivery
Mengmeng Long et al.
ACTA BIOMATERIALIA (2020)
First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions
S. V. Liu et al.
ANNALS OF ONCOLOGY (2020)
Design, Synthesis, and in Vitro Biological Evaluation of 14-Hydroxytylophorine-dichloroacetate Co-drugs as Antiproliferative Agents
Ziad Omran et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2019)
Boronic Analogues of (R)-6-O-Desmethylantofine as Anticancer Agents
Ziad Omran et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2019)
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Xinming Jing et al.
MOLECULAR CANCER (2019)
Selective cancer treatment via photodynamic sensitization of hypoxia-responsive drug delivery
Hua He et al.
NANOSCALE (2018)
Hypoxia-activated prodrugs and redox-responsive nanocarriers
Yun Zeng et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
6-OH-Phenanthroquinolizidine Alkaloid and Its Derivatives Exert Potent Anticancer Activity by Delaying S Phase Progression
Yuxiu Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Natural Products as Sources of New Drugs from 1981 to 2014
David J. Newman et al.
JOURNAL OF NATURAL PRODUCTS (2016)
Phenanthroindolizidine alkaloids from Tylophora atrofolliculata with hypoxia-inducible factor-1 (HIF-1) inhibitory activity
Cheng-Yu Chen et al.
RSC ADVANCES (2016)
Acid-mediated Lipinski's second rule: application to drug design and targeting in cancer
Ziad Omran et al.
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS (2014)
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
Christopher P. Guise et al.
CHINESE JOURNAL OF CANCER (2014)
Antofine-induced connexin43 gap junction disassembly in rat astrocytes involves protein kinase Cβ
Yu-Fang Huang et al.
NEUROTOXICOLOGY (2013)
Synthesis of substituted 5-bromomethyl-4-nitroimidazoles and use for the preparation of the hypoxia-selective multikinase inhibitor SN29966
Guo-Liang Lu et al.
TETRAHEDRON (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Antitumor Agents 295. E-Ring Hydroxylated Antofine and Cryptopleurine Analogues as Antiproliferative Agents: Design, Synthesis, and Mechanistic Studies
Xiaoming Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Targeting hypoxia in cancer therapy
William R. Wilson et al.
NATURE REVIEWS CANCER (2011)
Efficient and Chirally Specific Synthesis of Phenanthro-Indolizidine Alkaloids by Parham-Type Cycloacylation
Ziwen Wang et al.
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2010)
Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice
Mitomu Kioi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
The tumor microenvironment and metastatic disease
Sarah Jane Lunt et al.
CLINICAL & EXPERIMENTAL METASTASIS (2009)
Design of Anticancer Prodrugs for Reductive Activation
Yu Chen et al.
MEDICINAL RESEARCH REVIEWS (2009)
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Mark W. Dewhirst et al.
NATURE REVIEWS CANCER (2008)
Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A:: A role for NADPH:cytochrome P450 oxidoreductase under hypoxia
Chris P. Guise et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Detection and characterization of tumor hypoxia using pO2 histography
Peter Vaupel et al.
ANTIOXIDANTS & REDOX SIGNALING (2007)
Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents
Wenli Gao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Antitumor agents 251: Synthesis, cytotoxic evaluation, and structure-activity relationship studies of phenanthrene-based tylophorine derivatives (PBTs) as a new class of antitumor agents
Linyi Wei et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
Inhibition of cell growth and nuclear factor-κB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503
Her-Shyong Shiah et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Novel approaches for targeted cancer therapy
V Guillemard et al.
CURRENT CANCER DRUG TARGETS (2004)
Exploiting tumour hypoxia in cancer treatment
JM Brown et al.
NATURE REVIEWS CANCER (2004)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
Hypoxia - A key regulatory factor in tumour growth
AL Harris
NATURE REVIEWS CANCER (2002)
Inhibition of dihydrofolate reductase and cell growth activity by the phenanthroindolizidine alkaloids pergularinine and tylophorinidine:: the in vitro cytotoxicity of these plant alkaloids and their potential as antimicrobial and anticancer agents
KN Rao et al.
TOXICOLOGY IN VITRO (2000)
分享论文
